BeiGene appoints Titus Ball as principal accounting officer; amends director compensation

BeOne Medicines Ltd.

Titus Ball named principal accounting officer effective March 19, 2024; succeeded Julia Wang, who remains CFO.
Ball joined in Aug 2023 as VP, Chief Accounting Officer; prior roles at Carlisle, KPMG, PwC.
Independent director cash retainers increased: Nominating Committee chair to $20,000 (+$2K), members to $10,000 (+$1K).
No changes to equity award structure ($400K initial and annual grant, 50/50 options/RSUs).
Amended policy effective April 1, 2024; full text filed as Exhibit 10.1.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Julia Wang

Chief Financial Officer

ONC · BeOne Medicines Ltd.

Effective: 2024-03-19
Successor: Titus Ball
Filed: March 20, 2024, 7:59 PM ET

Mr. Ball assumes the role of principal accounting officer from Julia Wang, the Company’s Chief Financial Officer, who previously served as the Company’s principal financial officer and principal accounting officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Julia Wang changed role as Chief Financial Officer at BeOne Medicines Ltd..

Action: stepped down as principal accounting officer
Role: Chief Financial Officer

Exact text from the filing

Mr. Ball assumes the role of principal accounting officer from Julia Wang, the Company’s Chief Financial Officer, who previously served as the Company’s principal financial officer and principal accounting officer.

View on SEC.gov

BeOne Medicines Ltd. filing history →

Source: SEC EDGAR

accession 0001651308-24-000032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.